Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Cygnus XL brings cargo to the ISS for 1st time | Space photo of the day for Dec. 1, 2025 - 2Motivational Travel Objections for History Buffs
- 3Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- 4Dental Embed Developments: Upsetting Current Dentistry
- 5The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- Congo declares its latest Ebola outbreak over, after 43 deaths
- Farmers worry about rising cost of fertiliser
- Excited visitors for NASA's moon launch jockey for prime views
- Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- Understanding Various Sorts of Financial balances: An Extensive Outline
- Five held on suspicion of planning attack on German Christmas market
- From Novice to Master: Dominating a Side interest
